Saturday, July 5, 2014

Belinostat enters the Battle!

With the release of Belinostat, the FDA has made a big step forward, and once again points to the
importance of Oncology medications in the Histone deacetylators or drugs affecting primarily the epigenetic phenomena.   The challenge with these drugs is not only how to quantify the level of de-acetylation or methylation in the epigenetic zone, but measure some of the genes known to be located in the area and how they are affected. How DNMT1/DMAP1 react to these drugs (quantification needed...)  (not to confuse with DMT1, another total ball game altogether!)
De-acetylators have demonstrated activity in Leukemias, but this one was also tested in unknown primaries and lung cancers.  A question also remains, are these  important in NF-kB driven diseases or HSP90 overexpressions (Gastric cancers?).   Belinostat has been approved in Peripheral T cell lymphoma. (see also Vorinostat, released for Cutaneous T cell lymphoma).

1 comment:

Ralph said...

Hello mate nicce blog